All In Biotech

Drug Trial Radar · NCT04332653

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

215

Actual

Start

Jun 10, 2020

Primary completion

Nov 22, 2024

Study completion Jan 13, 2025

Sponsor

Lead sponsor
NeoImmuneTechIndustry
Sponsor type
Industry
Collaborators
Merck Sharp and Dohme LLC, Rahway, NJ, USA
First posted
Apr 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: * Safety and tolerability of NT-I7 in combination with pembrolizumab * Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) The main purpose of Phase 2a of this study is to assess the preliminary anti-tumor activity of NT-I7 in combination with pembrolizumab in participants with checkpoint inhibitor (CPI) treated and naïve relapsed and refractory (R/R) tumors. The main purpose of the Biomarker Cohort is to assess a potential correlation between tumor infiltrating lymphocytes (TILs) and clinical benefits in participants with CPI-naïve R/R ovarian cancer (OC).

Conditions

  • Any Advanced Solid Tumors
  • Triple Negative Breast Cancer
  • Non Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Microsatellite Stable Colorectal Cancer
  • Pancreatic Cancer
  • Ovarian Cancer

Interventions

  • NT-I7Drug

    Administered by intramuscular (IM) injection

  • pembrolizumab (KEYTRUDA®)Drug

    Administered by intravenous (IV) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs), Serious AEs (SAEs), Trial Treatment-related TEAEs and Trial Treatment-related SAEsTime frame: Up to 2 years and 3 months
  2. Phase 1b: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)Time frame: Up to 21 days
  3. Phase 2a (Arms I to Va): Objective Response Rate (ORR)Time frame: Up to 2 years
  4. Biomarker Cohort: Percentage of Area Occupied by Tumor-Infiltrating Lymphocytes (TILs)Time frame: Pre-treatment and post-treatment (maximum duration of treatment of approximately 2 years)

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Moffit Cancer Center

    Tampa, Florida

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • Duke University Medical Center

    Durham, North Carolina

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Mary Crowley Cancer Research

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.